Major Depressive Disorder, Multiple Sclerosis
Conditions
Keywords
MS, MDD
Brief summary
The main purpose of this study is to investigate the safety and tolerability of intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms as well as its effects on cognition. Although iTBS rTMS is approved for use, there have been no safety and tolerability evaluations of this form of rTMS in Multiple Sclerosis (MS).
Detailed description
The main purpose of this study is to investigate the safety and tolerability of intermittent Theta Burst (iTBS), its effectiveness in alleviating depressive symptoms, concomitant neuropsychiatric symptoms such as anxiety and fatigue in people with MS, as well as its effects on cognition. Although iTBS repetitive transcranial magnetic stimulation (rTMS) is approved for use in major depressive disorder (MDD), there have been no safety and tolerability evaluations of this form of rTMS in Multiple Sclerosis (MS) patient with MDD. Although iTBS rTMS has previously been found safe and effective for treating spasticity in people with MS, this will be the first study to investigate the safety and tolerability of Left Dorsolateral Prefrontal Cortex (L-DLPFC) iTBS rTMS for MDD in MS This study is designed as an open-label pilot study. Participants will undergo baseline evaluations to confirm a diagnosis of MDD and to assess your eligibility for rTMS treatment. If deemed eligible, participants will receive iTBS treatment. iTBS is a form of rTMS approved by Health Canada for treatment of MDD. iTBS rTMS treatment involves 3 minutes of non-invasive brain stimulation, 5 days a week, for 4 weeks, for a total of 20 treatments. While receiving iTBS rTMS, participants will be seen daily by the rTMS operator who is a mental health nurse. While receiving iTBS rTMS, participants will see the research coordinator and study psychiatrist on a weekly basis, to complete clinical assessments to evaluate their neuropsychiatric symptoms and assess any side effects from the rTMS procedure. As part of the suggested pathophysiological profile of depression the levels of inflammatory cytokines tumor necrosis factor ⍺ (TNF-⍺) and interleukin-6 (IL-6) have shown elevated concentration levels in plasma of depressed compared to non-depressed individuals. In this study, we aim to investigate the levels of these inflammatory cytokine markers and their change with iTBS.
Interventions
DEVICERepetitive transcranial magnetic stimulation
Left DLPFC iTBS rTMS
Sponsors
Sunnybrook Health Sciences Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study is designed as an open-label pilot study
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Men and women ≥18 and ≤70 years of age, inclusive. 2. History of MS confirmed by a neurologist. 3. Patients who are able and willing to give consent and able to adhere to treatment schedule and attend study visits, as determined by study psychiatrist 4. DSM-V diagnosis of Major Depressive Disorder (MDD) 5. Moderate severity with a Hamilton Depression Rating Scale (HAMD) at least 16 6. Patients have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening 7. Pass the TMS safety screening questionnaire 8. Women of childbearing potential must agree to use a barrier contraception method throughout the study.
Exclusion criteria
1. Active substance abuse or dependence in the last three months, except nicotine 2. Active suicidal intent 3. Currently pregnant (as determined by history and serum HCG) or lactating. 4. A diagnosis of Bipolar Disorder 5. A history of past or current psychotic symptoms 6. Diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), assessed by a study investigator to be primary and causing greater impairment than MDD 7. Having failed a course of ECT in the current episode or previous episode 8. Previous trial of rTMS 9. Personality disorder deemed to be primary pathology 10. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study 11. Clinically significant laboratory abnormality, in the opinion of the investigator 12. Unstable medical illness 13. Contraindication to rTMS, e.g. presence of cardiac pacemaker, intracranial implant, or metal in the cranium 14. Currently on more than 2 mg of lorazepam or equivalent 15. History of seizures, or currently on anticonvulsant for seizures 16. Concurrent use of a medication that may lower the seizure threshold, in the opinion of the investigator e.g. stimulant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in depressive symptoms | Baseline and 4 weeks post-treatment | The primary outcome measure will be the reduction in depressive symptoms as measured by the Hamilton Depression Rating Scale-17 at the end of the 4-week trial of iTBS rTMS. This will be measured as both a continuous variable (score on HAMD-17 at week 4 - score on HAMD-17 at week 0 pre-treatment) and a categorical one (i.e. the response rates of \>50% reduction from baseline HAMD-17 and remission rates defined as HAMD-17 \<7). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in anxiety and depressive symptoms | Baseline and 4 weeks post-treatment | Change in anxiety and depressive symptoms as measured by the self-report Hospital Anxiety and Depression Scale (HADS)-17 at the end of the 4-week trial of iTBS rTMS. |
| Change in fatigue, severity and impact | Baseline and 4 weeks post-treatment | Change in fatigue, severity and impact, measured by the self-report Fatigue Severity Scale (FSS) |
| Change in Neuropsychological function | Baseline and 4 weeks post-treatment | Change in Neuropsychological function, measured subjectively through the Perceived Deficits Questionnaire (PDQ-5) and objectively by the SDMT and computerized CANTAB neuropsychological tasks |
Countries
Canada
Contacts
Primary ContactAnusha Baskaran, PhD
Outcome results
None listed